Navigation Links
Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
Date:4/15/2009

s subtype), they are less likely to prescribe disease-modifying therapies to patients with clinically isolated syndrome (early-stage multiple sclerosis). This is despite clinical studies indicating that early initiation of disease-modifying therapies can delay progression of the disease, and specifically, delay disability progression.

"Those patients who do not start disease-modifying treatment right away represent an untapped opportunity for marketers of disease-modifying drugs," added Ms. Puffer. "Treatment rates could be improved, especially for patients with early stage disease, through increased awareness among both neurologists and primary care physicians, of the benefits surrounding early treatment initiation. These improvements would facilitate increased use of disease-modifying therapies."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS Lifelink: Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. P
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
2. New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option
3. American Legion Anticipates Institute of Medicine Report on Gulf War Veterans
4. Preterm Births Rise 36 Percent Since Early 1980s
5. Healthy Bones Program Reduces Hip Fractures by 37 Percent, Kaiser Permanente Study Finds
6. Leading Healthcare System Decreases MRSA Infection Rate by 53 Percent - Offers Protocol & Educational Materials Free of Charge to Other Organizations
7. Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel
8. Velos Set to Clear 50 Percent Market Penetration of Large U.S. Clinical Research Sites by Year End
9. The ED Conversation Dilemma: Forty Percent of Men with ED Dont Talk to Their Doctor, Survey Finds
10. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
11. A Drug With Efficacy Superior to That of Xenical at Inducing Weight Loss Would Earn a 40 Percent Patient Share in the Obesity Drug Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013 InspireMD, Inc. ("InspireMD" ... in embolic protection stents, today announced new 6-month ... Elevation Reperfusion) trial demonstrating that the MGuard Embolic ... eluting stents in all-cause mortality in ST segment ... trial were presented at the InspireMD STEMI Symposium ...
(Date:5/23/2013)... and PARIS , May 23, ... a leading developer and manufacturer of precision guided therapy ... coronary and peripheral vascular disease, today announced preliminary results ... I ndependent S tenosis E valuation) ... trial session at EuroPCR 2013. These prospective results confirm ...
(Date:5/23/2013)... 22. Mai 2013 Ranbaxy ... Tochtergesellschaft von Daiichi Sankyo Co., Ltd. ... 22. Mai die Maßnahmen bekannt, die ... hat, um sich der Angelegenheiten der ... http://www.daiichisankyo.com/media_investors/media_relations/press_releases/index.html ). Daiichi Sankyo ...
Breaking Medicine Technology:InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 2Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 4Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 5Ranbaxy kündigt Verbesserungen bei Geschäftsstandards und Qualitätssicherungsinitiativen an 2
... , July 27 BioElectronics Corp. (Pink Sheets: ... its distribution partner for Japan , YesDTC Holdings, Inc. ... staff of the pending review by Japanese government medical device ... review will take place on Wednesday, July 28th . ...
... , July 27 Codexis, Inc. (Nasdaq: CDXS ) today ... Leadership Forum, August 8-10, 2010 in Vail, CO. ... presentation on August 10 at 8:30 am Mountain Time . ... www.codexis.com .   , , ...
Cached Medicine Technology:BioElectronics and YesDTC Holdings Receive Japanese Regulatory Review Date 2Codexis to Present at the Pacific Crest Technology Leadership Forum 2
(Date:5/23/2013)... Netsmart today announced it is ranked ... information technology (HIT) providers for 2013. , The HCI 100 ... Healthcare Informatics magazine. Netsmart’s ranking of #49 is up ... growth is largely due to our commitment to helping organizations ... where resources are scarce, the demand for care is unprecedented ...
(Date:5/23/2013)... 2013 Applied PilotFish Healthcare Integration ... it has added support for the Direct Protocol to ... for Healthcare. In addition to the product’s already included ... and Web Services, it now offers support for the ... a specification of the Direct Project and ...
(Date:5/23/2013)... May 23, 2013 Aero Fulfillment Services, ... selected by NewWave Biosciences to be the sole fulfillment ... care professionals. , Brad Cole, CEO New Wave ... reasons including their central location, e-commerce experience with both ... and overall end-to-end solution that will expand as our ...
(Date:5/23/2013)... York (PRWEB) May 23, 2013 Maintaining ... today launches its Summer Health Campaign. Kicking off in ... to offering a luxury bed for everyone and to ... overall health and well-being. , May is Better Sleep ... by the Better Sleep Council due to the Centers ...
(Date:5/23/2013)... Sika Sarnafil , the worldwide market ... Imperial Roof Systems of Iowa as the Recycling Project ... quality during the re-roofing of the SuperTarget retail store ... Sarnafil Elite contractor and one of Target’s Preferred Tier ... to sustainable building practices and they are a worthy ...
Breaking Medicine News(10 mins):Health News:Netsmart Named to Healthcare Informatics Top 100 List 2Health News:PilotFish Expand’s Healthcare Integration Capabilities with Support for the New Direct Protocol in Its Latest Product Release 2Health News:NewWave Biosciences Chooses Aero Fulfillment for e-Commerce Distribution of New Product to Reduce Inflammation 2Health News:DUXIANA®, Quality Bed Innovator, Celebrates Better Sleep Month and Launches Summer Health Campaign 2Health News:Sika Sarnafil Announces Recycling Project of the Year Winner 2
... recent research has found that pregnant womens contact with ... birth weight. ,The National Research Centre ... the study, together with colleagues from the French Institute ... GSF. ,In this study, the scientists have ...
... has justified placing Paris Hilton under house arrest by citing ... Judge Michael T Sauer who ordered her back to ... doctors. ,On Larry Kings show, Larry Waldie, who had ... didn't care, and that he even hinted that Hilton was ...
... The UN has declared Galapagos Island in danger. The ... tourism is threatening the environment that helped shape ... first place on the planet officially designated as a ... danger as booming tourism and immigration threaten giant tortoises ...
... care is taking a heavy toll in England, both in ... 189m every year , according to a report published today ... ,The report - Wasted Money, Wasted Lives - concludes ... year from epilepsy, 69,000 people are living with unnecessary seizures, ...
... need to be cautious according to new research presented for ... ,Unlike approved generic drug names, brand names of ... that a branded product in one country is the same ... in other counties. ,A new study by regulatory ...
... researchers have established that the affordable drug, Gatifloxacin, is ... ,The study was conducted by a team of ... Lalitpur in Kathmandu, Nepal. ,As part of ... drug with Cefixime, which is currently recommended by the ...
Cached Medicine News:Health News:Fine Particulate Matter from Traffic may Reduce Unborn Babies Birth Weight 2Health News:Galapagos on UN Endangered List 2Health News:Blunders in Epilepsy Care Cost Lives, and Money UK Report 2
... are constructed of a patented ... polyvinyl acetal sponge. Each device ... to both surgeon and patient, ... firm enough to gently manipulate ...
... KeraCel Ophthalmic Products are constructed ... of lint-free MEROCEL polyvinyl acetal ... to be beneficial to both ... absorbent, and yet firm enough ...
... Ophthalmic Products provide the ... free products for unparalleled ... cleaning of fine microsurgical ... material is highly absorbent, ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Medicine Products: